Ozempic Price Without Insurance: What You'll Actually Pay

The retail list price of Ozempic in the US is approximately $935 per month (for the 1 mg dose, one pen). Like most branded medications, the list price functions primarily as a starting point for negotiations between manufacturers and insurers — most patients who access Ozempic through legitimate channels pay considerably less. Here is what to expect across each payment path.

With commercial insurance

If your insurance covers Ozempic for type 2 diabetes (its approved indication), your actual out-of-pocket cost depends on your plan's formulary tier, deductible, and copay structure. Common scenarios:

• Preferred tier coverage: $25–$75/month after deductible
• Non-preferred tier: $100–$250/month or a percentage of the list price
• Not on formulary: Full cost or prior authorisation required before coverage begins

Ozempic is covered more broadly than Wegovy because it is approved for diabetes, which most plans consider a priority indication. If your insurer covers it and you have a diabetes diagnosis, your copay is often manageable.

Novo Nordisk savings card (commercial insurance)

Novo Nordisk offers an Ozempic savings card that can reduce copays to as low as $25 per fill for eligible patients with commercial insurance. Eligibility is restricted to:

• Patients with commercial (private/employer) insurance — not government payers
• The card covers the gap between your copay and a set cap
• Income and plan restrictions apply — check the Ozempic official site for current terms

This is the most effective cost-reduction tool for insured patients and is worth enrolling in if you qualify.

Without insurance — cash pay at pharmacy

At retail price with no insurance or discount card, Ozempic runs approximately $900–$1,000 per month. GoodRx and similar discount services can reduce this to roughly $800–$900/month at participating pharmacies — meaningful savings but still significant for a long-term medication.

Patient assistance for uninsured, low-income patients

Novo Nordisk's NovaCare patient assistance programme provides free Ozempic to patients who are uninsured, underinsured, or cannot afford their medication, subject to income criteria. Applications go through your prescriber. If you qualify, this is the best outcome available.

Compounded semaglutide as the alternative

For patients paying cash who find brand Ozempic unaffordable, compounded semaglutide is the most common alternative. Telehealth platforms offer prescriptions for compounded semaglutide — the same active molecule — typically at $150–$500/month all-in.

Key differences from brand Ozempic:

• Not FDA-approved as a finished product
• Made by compounding pharmacies (503A or 503B); quality depends on the specific pharmacy
• Pricing includes the consultation and medication, delivered directly
• The active ingredient and mechanism are identical to brand Ozempic

The real cost most people pay

In practice, the population accessing Ozempic falls into a few buckets:

• Insured with diabetes coverage + savings card: $25–$75/month
• Insured, no savings card: $75–$250/month
• Uninsured, patient assistance: $0 (if income-qualified)
• Cash pay, compounded semaglutide: $150–$500/month
• Cash pay, brand Ozempic: $800–$1,000/month

Prices and programme terms change frequently. Always verify current costs directly with Novo Nordisk, your pharmacy, and any telehealth provider before making decisions. The figures here reflect publicly available information as of May 2026.